Background: Sickle cell disease is characterized by the occurrence of acute disability and
progressive organ damage, and it is one of the most common and severe monogenic disorders around
the world. Since hydroxycarbamide is the only drug approved by the Food and Drug Administration
(FDA) to treat this disease, it is necessary to continue the development of new drug candidates to improve
its treatment. Two of a series of phthalimide derivatives have shown great potential as a new drug
Methods: Accordingly, a UHPLC quantitation method was developed and used to determine the chemical
and plasma stability of these compounds. Their experimental log P values are presented here for the
Results: Method validation results were within appropriate limits for the application of UHPLC. The
experimental log P was 2.56 for LAPDESF-SCD03 and 2.59 for LAPDESF-SCD04. The chemical stability
of LAPDESF–SCD03 was better at pH 1.2, while for LAPDESF-SCD04, there was a significant
reduction in drug at the 30-minute time point at pH 1.2 and 7.4. In the plasma hydrolysis study, LAPDESF-
SCD03 showed a significant decay within 5 minutes, while LAPDESF-SCD04 was significantly
lower than at time zero just in 15 min. Similar decay rate constants were observed for the two compounds.
Conclusion: Both compounds have a stability profile that may be related to their proved effectiveness.